ClinicalTrials.gg
Active, not recruitingNCT05287373COMFORTUpdated Nov 13, 2026Results posted

Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain

An interventional study of Nalu Neurostimulation System for PNS and conventional medical management in Peripheral Neuralgia and Chronic Pain, sponsored by Nalu Medical, Inc.. Active, not recruiting at 13 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nalu Medical, Inc. (part of Boston Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Chronic Pain by Boston Scientific Corporation — 3 open to participants now, 7 under way, none of them phase 3. Chronic Pain · Boston Scientific Corporation.

Enrollment
10th of 32
131 · median 46
Started
2022
with 1 other
No phase
28 of 37
1 open now
Registered
33rd of 37
by date

Among the 37 studies in Chronic Pain by Boston Scientific Corporation, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 28 with no phase, and was the 33rd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

3 of the 37 studies in Chronic Pain by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Chronic Pain by Boston Scientific Corporation, or all of them as a file.
02

Study summary

This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or post-surgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.

Read the detailed description

Multi-center, prospective, open-label, randomized controlled trial (RCT) comparing PNS plus CMM with CMM alone. Subjects will be randomized to receive:

Arm 1: Nalu Neurostimulation System for PNS plus CMM Arm 2: CMM alone Consented subjects will receive a baseline evaluation and then be randomized 2:1 into one of two arms: 1) PNS+CMM arm or 2) CMM arm. Subjects assigned to Arm 1 will undergo a trial implant period using best clinical practices. Those subjects who pass the trial implant will receive the permanent implant. At the 3-month end point, subjects in Arm 2 will be given the option to crossover into Arm 1 beginning with a trial implant. All Arm 1 patients receiving a permanent implant will be followed for a total of 36 months after permanent implantation. Arm 2 patients who do not crossover will be followed for a total of 36 months from randomization.

03

Conditions studied

  • Peripheral Neuralgia
  • Chronic Pain

Browse trials for

Keywords

  • PNS
  • Peripheral nerve stimulation
  • mIPG
  • peripheral nerve stimulator
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is between 18 to 80 years of age at the time of enrollment.
  2. Subject would have been prescribed PNS therapy regardless of participation in this study; the use of the Nalu device must be on-label.
  3. Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle):Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment; Mononeuropathy, specified or unspecified or in diseases classified elsewhere; Other neuralgia or neuropathic pain; Osteoarthritic pain.
  4. Subject has chronic (defined as at least 6 months duration), intractable peripheral neuropathic pain, exclusive of the craniofacial region; any nociceptive pain must be less prominent than the neuropathic pain. Pain should have a predominant neuropathic component as per the investigator's clinical assessment.
  5. Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening.
  6. Subject is willing to cooperate with the study requirements including, compliance with the study procedures and completion of all study visits.
  7. Subject reported stable pain (non-escalating) for 60 days prior to signing .
  8. Subject is currently receiving CMM and has had stable pain medication use and dosage for 30 days prior to signing informed consent.
  9. Subject is psychologically qualified to receive a peripheral nerve stimulator as per the clinician's standard clinical practice and judgment and does not have psychological condition(s) that would interfere with their ability to accurately report outcomes or complete study procedures.
  10. Subject has demonstrated the ability to appropriately place the adhesive clip in the location where the IPG is most likely to be implanted. Alternatively, subject is able to appropriately use the relief belt and/or limb cuff to keep the Therapy Disc in place.

Exclusion criteria

Exclusion Criteria:

  1. Subject currently has an active implantable medical device such as a drug pump, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, deep brain stimulator, and/or cardiac pacemaker.
  2. Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant)
  3. Pain is completely absent at rest.
  4. Patient has clinical evidence of complex regional pain syndrome (CRPS), peripheral neuralgia of metabolic origin, post-herpetic neuralgia, biochemical evidence of a metabolic or genetic neuropathy (e.g., Charcot'- Marie- Tooth Disease) or mixed motor/sensory polyneuropathy.
  5. Subject has a medical condition that would prevent them from participating in the current study per investigator's or medical monitor's judgment.
  6. Subject has had a successful (≥ 50% pain relief) interventional procedure within the past 3 months to treat the same pain condition(s) being examined in this study including, nerve blocks.
  7. Uncontrolled depression or uncontrolled psychiatric disorders
  8. Subject is currently participating in another clinical investigation with an active treatment arm.
  9. Subject is allergic or sensitive to materials used in the device components including, skin adhesives or does not tolerate the wearable aspect of the device.
  10. Subject has pending or ongoing legal issues (including unresolved worker's compensation claims or equivalent) or other conflicting secondary gain issues related to their chronic pain condition.
  11. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease that has not been medically corrected.
  12. Subject has an active systemic infection.
  13. Subject is unable to read and/or write in English or give .
  14. Subject has a of less than 1 year.
  15. Subject has an active malignant neoplasm ( or local) or evidence of paraneoplastic syndrome.
  16. Subject with uncontrolled diabetes mellitus, showing signs of diabetic neuropathy, as evidenced by a neurological exam and a test.
  17. Subject has evidence of an alcohol or drug dependency within the last 6 months prior to enrollment.
  18. Subject is pregnant (if female and sexually active, subject must be using a reliable form of , be surgically sterile or be at least 1 year ).
  19. Subject is nursing/breastfeeding.
  20. Subject is on ≥90 mg-morphine equivalents per 24 hours.
  21. Subject has undergone an ablative treatment of the target peripheral nerve, or proximal nerve trunk giving rise to the target nerve, or dorsal roots (and DRGs) that ultimately make up the target nerve. No ablative procedures directed at the spinal cord, dorsal roots, or peripheral nerve(s) being treated in the study. To note, subjects who have undergone RF ablation of the dorsal rami, cool pulsed RF of the facet innervation may be considered for enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Active comparator
    PNS Therapy plus Conventional Medical Management

    peripheral nerve stimulator plus conventional medical management

    Device: Nalu Neurostimulation System for PNS · Other: conventional medical management

  • Other
    Conventional Medical Management

    Control arm conventional medical management only

    Other: conventional medical management

Interventions

  • DeviceNalu Neurostimulation System for PNS

    The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator

    Also known as: Nalu PNS

  • Otherconventional medical management

    Conventional medical management

06

What researchers measure

Primary outcomes

  1. Effectiveness: Responder Rates Between Groups

    Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).

    Time frame: 3-months

Secondary outcomes

  1. Functional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month

    Change in patient reported ODI from baseline with comparison between groups. The ODI is a patient reported questionnaire used to measure functional disability and daily living impact. The ODI consists of ten topics, each scored from 0-5- pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life (optional), social life and traveling. The total score is used to calculate the percentage of disability from 0-100% and categorized as minimal, moderate, severe disability, crippled and bed bound. A lower score, compared to baseline, indicates improvement in ODI.

    Time frame: 3 months

  2. Functional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline

    Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up compared to baseline, indicates an improvement in depression symptoms and mood.

    Time frame: 3-months

  3. Functional Outcomes: Brief Pain Inventory (BPI; Interference)

    Brief Pain Inventory is a validated questionnaire to measure pain severity and how pain interferes with daily functioning. Pain Interference (general activity, mood, walking, work, relationships, sleep, enjoyment of life; 0-10 scale where, 0=Does not interfere and 10= completely interferes)

    Time frame: 3-months

  4. Functional Outcomes: Brief Pain Inventory (BPI; Severity)

    Brief Pain Inventory is a validated questionnaire to measure pain severity using a 0-10 rating scale where, 0= no pain and 10= pain as bad as you can imagine.

    Time frame: 3-months

  5. Functional Outcomes: Quality of Life Using the EQ-5D-5L

    The EQ-5D-5L is a standardized, self-reported questionnaire used to measure health related quality of life across 5 dimension i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels from no problems to extreme problems. This produces a 5-digit code which is converted to an index value based on the health of the general population where a higher score indicates better health (0-1).

    Time frame: 3-months

07

Results

Posted Nov 13, 2026

Participant flow

Recruitment commenced on 23 February 2022 and completed on 29 March 2023. Recruitment carried out at 12 pain management centers across the United States.

Participant flow — Overall Study
MilestonePNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Started5831
Completed4329
Not completed152
Withdrew: Physician decision30
Withdrew: Trial failure10
Withdrew: Withdrawal by subject62
Withdrew: Adverse event20
Withdrew: Missed visit30

Outcome measures

PrimaryEffectiveness: Responder Rates Between Groups

Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).

Time frame:
3-months
Reported as:
Count of participants · Participants
Effectiveness: Responder Rates Between Groups
ParticipantsPNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Effectiveness: Responder Rates Between Groups361
SecondaryFunctional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month

Change in patient reported ODI from baseline with comparison between groups. The ODI is a patient reported questionnaire used to measure functional disability and daily living impact. The ODI consists of ten topics, each scored from 0-5- pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life (optional), social life and traveling. The total score is used to calculate the percentage of disability from 0-100% and categorized as minimal, moderate, severe disability, crippled and bed bound. A lower score, compared to baseline, indicates improvement in ODI.

Time frame:
3 months
Reported as:
Mean · percentage of disability
Functional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month
percentage of disabilityPNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Functional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month22.7 ± 15.440.0 ± 17.9
SecondaryFunctional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline

Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up compared to baseline, indicates an improvement in depression symptoms and mood.

Time frame:
3-months
Reported as:
Mean · score on a scale
Functional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline
score on a scalePNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Functional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline6.40 ± 7.09.0 ± 7.86
SecondaryFunctional Outcomes: Brief Pain Inventory (BPI; Interference)

Brief Pain Inventory is a validated questionnaire to measure pain severity and how pain interferes with daily functioning. Pain Interference (general activity, mood, walking, work, relationships, sleep, enjoyment of life; 0-10 scale where, 0=Does not interfere and 10= completely interferes)

Time frame:
3-months
Reported as:
Mean · score on a scale
Functional Outcomes: Brief Pain Inventory (BPI; Interference)
score on a scalePNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Functional Outcomes: Brief Pain Inventory (BPI; Interference)2.32 ± 2.055.73 ± 2.02
SecondaryFunctional Outcomes: Brief Pain Inventory (BPI; Severity)

Brief Pain Inventory is a validated questionnaire to measure pain severity using a 0-10 rating scale where, 0= no pain and 10= pain as bad as you can imagine.

Time frame:
3-months
Reported as:
Mean · score on a scale
Functional Outcomes: Brief Pain Inventory (BPI; Severity)
score on a scalePNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Functional Outcomes: Brief Pain Inventory (BPI; Severity)2.93 ± 1.956.41 ± 1.79
SecondaryFunctional Outcomes: Quality of Life Using the EQ-5D-5L

The EQ-5D-5L is a standardized, self-reported questionnaire used to measure health related quality of life across 5 dimension i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels from no problems to extreme problems. This produces a 5-digit code which is converted to an index value based on the health of the general population where a higher score indicates better health (0-1).

Time frame:
3-months
Reported as:
Mean · score on a scale
Functional Outcomes: Quality of Life Using the EQ-5D-5L
score on a scalePNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Functional Outcomes: Quality of Life Using the EQ-5D-5L0.78 ± 0.130.63 ± 0.14

Adverse events

Collected over 3-months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PNS Therapy Plus Conventional Medical Management0/58 (0%)2/58 (3.4%)11/58 (19%)
Conventional Medical Management0/31 (0%)0/31 (0%)0/31 (0%)
Most frequent serious events
Most frequent serious events
EventPNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Hospitalization for diverticulitisGastrointestinal disorders1/580/31
Laparoscopic Endometriosis ExcisionReproductive system and breast disorders1/580/31
Most frequent other events
Most frequent other events
EventPNS Therapy Plus Conventional Medical ManagementConventional Medical Management
Skin irritation including redness, itching and bumpinessMusculoskeletal and connective tissue disorders5/580/31
Infection at implant siteInfections and infestations3/580/31
Migration (IPG or Lead)Product Issues3/580/31

Baseline characteristics

The baseline analysis population is a modified intent to treat (mITT) population as pre-defined in the Statistical Analysis Plan (SAP). The mITT is defined as "all randomized subjects receiving a permanent implant and having an implant at the time of analysis in the Active Arm and all randomized subjects in the Control Arm".

Age, Continuous
Age, Continuous(years)PNS Therapy Plus Conventional Medical ManagementConventional Medical ManagementTotal
Mean57.6 ± 11.557.03 ± 12.557.4 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PNS Therapy Plus Conventional Medical ManagementConventional Medical ManagementTotal
Female322254
Male14923
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PNS Therapy Plus Conventional Medical ManagementConventional Medical ManagementTotal
Hispanic or Latino549
Not Hispanic or Latino372461
Unknown or Not Reported437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PNS Therapy Plus Conventional Medical ManagementConventional Medical ManagementTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American426
White372562
More than one race000
Unknown or Not Reported549
Years since diagnosis
Years since diagnosis(years)PNS Therapy Plus Conventional Medical ManagementConventional Medical ManagementTotal
Mean4.1 ± 4.86.3 ± 6.55 ± 5.6
Areas of Pain
Areas of Pain(Participants)PNS Therapy Plus Conventional Medical ManagementConventional Medical ManagementTotal
Low Back241438
Knee8816
Shoulder7310
Foot/Ankle7613
08

Study locations

13 sites
09

References and documents

Publications

  • Hatheway J, Hersel A, Engle M, Gutierrez G, Khemlani V, Kapural L, Moore G, Ajakwe R, Trainor D, Hah J, Staats PS, Makous J, Heit G, Kottalgi S, Desai MJ; COMFORT Study Group. Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 12-month results from the COMFORT-randomized controlled trial. Reg Anesth Pain Med. 2026 Mar 5;51(3):278-284. doi: 10.1136/rapm-2024-106099. PubMed 39572166 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Dec 2023, 21 months.

Results were first posted in Nov 2026, 2 years 11 months after primary completion.

Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 21 months is close to that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Mar 18, 2022
StartActual
Feb 23, 2022
Primary completionActual
Dec 11, 2023
CompletionEst.
Jun 11, 2027was Sep 2026
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Study completion
Sep 30, 2026→Jun 11, 2027
Nov 13, 2026
Enrollment
89→131
Nov 13, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedEffectiveness: Responder rates between groupsRates Between GroupsTime frame: 3-months
  • RemovedSafety: Rate of serious and non-serious adverse events between groupsTime frame: 3-months
Nov 13, 2026
Documents
Secondary outcomes
5 added, 6 removed
What changed in the outcomes
  • AddedFunctional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-monthTime frame: 3 months
  • AddedFunctional Outcomes: Change in Beck's Depression Inventory (BDI) Score From BaselineTime frame: 3-months
  • AddedFunctional Outcomes: Brief Pain Inventory (BPI; Interference)Time frame: 3-months
  • AddedFunctional Outcomes: Brief Pain Inventory (BPI; Severity)Time frame: 3-months
  • AddedFunctional Outcomes: Quality of Life Using the EQ-5D-5LTime frame: 3-months
  • RemovedResponder Rates between groups at 6-monthsTime frame: 6 months
  • RemovedResponder Rates between groups at 12-monthsTime frame: 12-months
  • RemovedResponder Rates between groups at 24-monthsTime frame: 24-months
  • RemovedResponder Rates between groups at 36-monthsTime frame: 36-months
  • RemovedFunctional Outcomes: Change in ODI, BDI, EQ-5D, BPI from baselineTime frame: 3, 6, 9, 12, 18, 24, 30 and 36 months
  • RemovedSafety AssessmentTime frame: 3, 6, 9, 12, 18, 24, 30 and 36 months
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Study completion Sep 30, 2026→Jun 11, 2027
    Enrollment 89→131
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedEffectiveness: Responder rates between groupsRates Between GroupsTime frame: 3-months
    • RemovedSafety: Rate of serious and non-serious adverse events between groupsTime frame: 3-months
    Secondary outcomes 5 added, 6 removed
    What changed in the outcomes
    • AddedFunctional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-monthTime frame: 3 months
    • AddedFunctional Outcomes: Change in Beck's Depression Inventory (BDI) Score From BaselineTime frame: 3-months
    • AddedFunctional Outcomes: Brief Pain Inventory (BPI; Interference)Time frame: 3-months
    • AddedFunctional Outcomes: Brief Pain Inventory (BPI; Severity)Time frame: 3-months
    • AddedFunctional Outcomes: Quality of Life Using the EQ-5D-5LTime frame: 3-months
    • RemovedResponder Rates between groups at 6-monthsTime frame: 6 months
    • RemovedResponder Rates between groups at 12-monthsTime frame: 12-months
    • RemovedResponder Rates between groups at 24-monthsTime frame: 24-months
    • RemovedResponder Rates between groups at 36-monthsTime frame: 36-months
    • RemovedFunctional Outcomes: Change in ODI, BDI, EQ-5D, BPI from baselineTime frame: 3, 6, 9, 12, 18, 24, 30 and 36 months
    • RemovedSafety AssessmentTime frame: 3, 6, 9, 12, 18, 24, 30 and 36 months
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05287373
Lead sponsor
Nalu Medical, Inc.
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Feb 23, 2022
Primary completion
Dec 11, 2023
Completion
Jun 11, 2027 (estimated)
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Patrick Martin
study director · Nalu Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion